Chronic Weight Management
Definition
The long-term medical management of obesity using lifestyle interventions, pharmacotherapy, and sometimes surgical approaches to achieve and maintain clinically meaningful weight reduction.
Chronic Weight Management
Chronic weight management refers to the sustained, multidisciplinary approach to treating obesity as a chronic relapsing disease rather than a condition amenable to short-term intervention. This paradigm recognizes that obesity involves persistent alterations in energy homeostasis, appetite regulation, and metabolic set points that resist weight loss and promote weight regain. Effective chronic weight management typically combines behavioral modifications (dietary changes, increased physical activity, and cognitive behavioral strategies) with pharmacotherapy and, in eligible patients, metabolic or bariatric surgery. The goal is to achieve and sustain a clinically meaningful weight reduction, generally defined as at least 5% of initial body weight, which has been associated with improvements in cardiometabolic risk factors.
The development of incretin-based therapies has transformed the pharmacological landscape of chronic weight management. Older anti-obesity medications produced modest weight loss of 3-7% and were limited by tolerability and safety concerns. In contrast, GLP-1 receptor agonists such as semaglutide and dual or triple agonists such as tirzepatide and retatrutide have demonstrated weight reductions of 15-25% or more in clinical trials, approaching the efficacy of some bariatric surgical procedures. However, clinical evidence consistently shows that weight regain occurs upon treatment discontinuation, reinforcing the need for long-term or indefinite pharmacotherapy in many patients.
Clinical Relevance to Retatrutide
Retatrutide represents a significant advancement in chronic weight management due to its triple agonism of GLP-1, GIP, and glucagon receptors. In phase 2 clinical trials, retatrutide produced mean weight reductions exceeding 24% at the highest doses over 48 weeks, among the largest reductions observed with any pharmacological agent. The dose-escalation strategy employed in retatrutide trials helps mitigate gastrointestinal adverse events during treatment initiation, improving tolerability and adherence. As with other anti-obesity pharmacotherapies, maintenance therapy with retatrutide is expected to be necessary to sustain weight loss, and ongoing studies are evaluating its long-term efficacy and safety profile for chronic weight management.